Glenmark Ordered to Pay $16 Million for At-Risk Launch of Tarka

A federal court jury has upheld Sanofi-Aventis and Abbott Laboratories’ patent on the anti-hypertensive drug Tarka and ordered Glenmark Pharmaceuticals to pay $16 million in damages following its at-risk launch of a generic version of the drug. In a decision reached in the U.S. District Court for the District of New Jersey, the jury found that Sanofi and Abbott’s ’244 patent on Tarka (trandolapril/verapamil HCl) was valid and had been infringed by Glenmark. That marks a change from last year, when the same court declined to decide the case outright, ruling that Glenmark had presented enough evidence questioning the legality of the ’244 patent for the case to proceed.
Generic Line